David Fandrei

6PUBLICATIONS

118CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Humoural immunology and immunochemistry

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jun 12, 2026

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Mar 31, 2025

Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders.

David Fandrei, Jean Pegliasco, Florence Pasquier

|Feb 21, 2025

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.

Till Braun, Michael Rade, Maximilian Merz

|Dec 05, 2024

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.

Maximilian Merz, Danai Dima, Hamza Hashmi

|Oct 23, 2024

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

David Fandrei, Sabine Seiffert, Michael Rade

|Dec 20, 2023

Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M.

David Fandrei, Tony Huynh, Marie Sébert

Pageof 1

Frequent Collaborators

Maximilian Merz

Vladan Vucinic

Nico Gagelmann

Friederike Schmitz

Tobias A W Holderried

Friedrich Stölzel

Fabian Müller

Uwe Platzbecker

Kristin Reiche

Patrick Born

Frequent Collaborators

Maximilian Merz

Vladan Vucinic

Nico Gagelmann

Friederike Schmitz